NL-OMON39710已完成2 期
COOLing for Ischaemic Stroke Trial. A phase II randomised clinical trial. - COOLIST: COOLing for Ischaemic Stroke Trial
niversitair Medisch Centrum Utrecht0 个研究点目标入组 48 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. A clinical diagnosis of acute ischaemic stroke;
- •2. A possibility to initiate cooling within 4.5 hours of stroke onset. Onset time for patients who awoke with symptoms is defined as the last time the patient was awake without symptoms of stroke;
- •3. Score on the National Institutes of Health Stroke Scale (NIHSS) >= 6;
- •4. Age >= 18 years;
- •5. Written informed consent by the patient or a legal representative.
排除标准
- •1. Evidence from a CT or MRI scan or from other pre-randomisation investigations of an intracranial haemorrhage, a brain tumour, encephalitis, or any diagnosis other than acute ischaemic stroke likely to be the cause of the symptoms. Haemorrhagic transformation of the infarct is not an exclusion criterion, except when there is a parenchymal haematoma covering more than 30% of the infarcted area, with significant space-occupying effect, or when there is a bleeding remote from the infarcted area (PH2 on Fiorelli*s scale);
- •2. Conditions that may be complicated by hypothermia, such as haematological dyscrasias(including oral anticoagulant treatment with INR >=1.7 or a platelet count < 100.10exp9/L), severe pulmonary disease, severe heart failure (defined as a NYHA score of III or IV), myocardial infarction within the previous 3 months, angina pectoris in the previous three months, severe infection with a CRP > 50 mg/L, or a clinical diagnosis of sepsis;
- •3. Blood oxygen saturation below 92% without use of oxygen therapy or below 94 % with a maximum of 2 L/min oxygen delivered nasally;
- •4. Bradycardia (<40 beats/min);
- •5. Body weight > 120 kg;
- •6. Pre-stroke score on the modified Rankin Scale (mRS) > 2;
- •7. Allergy to pethidine or buspirone, use of a monoamine oxidase inhibitor in the previous 14 days, hepatic or severe renal dysfunction, or asthma. Severe hepatic dysfunction is defined as liver enzymes increased above two times above the upper limit of normal, and severe renal dysfunction as a glomerular filtration rate <= 30 ml/min.;
- •8. Pregnancy. Women of childbearing potential are excluded unless a negative test for pregnancy has been obtained prior to randomization;
- •9. Other serious illness that may confound treatment assessment;
- •10. Previous participation in this trial.
研究者
相似试验
尚未招募
不适用
COOLing for Ischaemic Stroke Trial.acute ischaemic strokeNL-OMON21707niversity Medical Center Utrecht48
招募中
2 期
An investigator-initiated clinical trial of TM5614 for SSc-ILDInterstitial lung disease associated with systemic sclerosisD012595JPRN-jRCT2021230022Asano Yoshihide50
进行中（未招募）
不适用
Essai thérapeutique de phase II séquentiel non randomisé non contrôlé, multicentrique de traitement par everolimus de la maladie de Kaposi classique ou endémique. - Rad KaposiMedDRA version: 9.1Level: LLTClassification code 10023287Term: Kaposi's sarcoma classicalMaladie de Kaposi classique ou endémiqueEUCTR2007-000974-22-FRInserm
撤回
不适用
A Phase 1b, randomized, partially double-blind, placebo-controlled study to assess the pharmacokinetics, safety, and tolerability of multiple doses of orally administered JNJ-53718678 in infants hospitalized with RSV infectio10047438respiratory tract infectionRespiratory syncytial virus infectionNL-OMON43180Janssen Science Ireland UC3
撤回
2 期
A Phase II/III seamless, randomised, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for the treatment of symptomatic, non-hospitalized adults with mild to moderate COVID-19.Coronavirus Disease 2019 (COVID-19)severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1004743810024970NL-OMON51124Boehringer Ingelheim10